We stand up for novel and effective drugs
“because we see our patients fighting…”
「KPMG Global Tech Innovator Competition in Japan 2023」にて当社の和田が、核酸医薬の安全性を飛躍的に向上させるBROTHERS核酸を用いた事業の内容についてピ
Our company started with a consistent philosophy of our founder, Mariko Harada-Shiba, M.D., Ph.D., a medical doctor and a researcher; “to save patients we see by all means.” We are seeing nucleic acid-based therapeutic drugs as a panacea for various intractable and difficult-to-treat diseases.
Proteins are very fundamental and essential components of our bodies, whereas it is a fact that malfunction of them is also involved in many diseases. Protein information is stored in DNA and is extracted as messenger RNA (mRNA) when needed. A nucleic acid drug (called antisense) can bind to this mRNA and suppress the production of disease-related proteins. We believe that this method will lead to the treatment of many diseases for which there have been no effective drugs.
We have succeeded in creating a unique nucleic acid drug discovery platform by utilizing the excellent technologies built at the National Cerebral and Cardiovascular Center, as well as Osaka University, Nagasaki University, Tokushima Bunri University, and others.